# Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

> **NCT02846376** · PHASE1 · TERMINATED · sponsor: **Hackensack Meridian Health** · enrollment: 8 (actual)

## Conditions studied

- Acute Myeloid Leukemia and Myelodysplastic Syndrome

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02846376
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-08
- **Primary completion:** 2023-12-21
- **Final completion:** 2023-12-21
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Lack of Enrollment
- **Last updated:** 2024-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02846376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02846376, "Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02846376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*